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Background
After more than half a century of modern psychophar-
macology, with billions of dollars spent on antidepres-
sants annually world-wide, we lack good evidence to
guide our everyday decisions in conducting antidepres-
sant treatment of patients with major depression. First
we did not know which antidepressant to use as first
line treatment. Second we do not know which dosage
we should be aiming at with that antidepressant.
Because more than half of the patients with major
depression starting treatment do not remit after ade-
quate trial with the first agent, they will need a second
line treatment. Dose escalation, augmentation and
switching are the three often recommended second line
strategies but we do not know which is better than the
others. Moreover, we do not know when to start consid-
ering this second line treatment. The recently published
multiple-treatments meta-analysis of 12 new generation
antidepressants has provided some partial answers to
the first question [1]. Starting with these findings, this
proposed trial aims to establish the optimum 1
st line
and 2
nd line antidepressant treatment strategy among
adult patients with a non-psychotic unipolar major
depressive episode.
Methods/design
SUN(^_^)D, the Strategic Use of New generation antide-
pressants for Depression, is an assessor-blinded, parallel-
group, multi-centre, pragmatic randomised controlled
trial. The trial composes three-steps [2]. Step I is a
cluster-randomised trial comparing titration up to the
minimum vs maximum of the recommended dose range
among patients starting with sertraline. The primary
outcome is the change in the Patient Health Question-
naire (PHQ)-9 scores administered by a blinded rater
via telephone at week 1 through 3. Step II is an indivi-
dually randomised trial comparing staying on sertraline,
augmentation of sertraline with mirtazapine, and switch-
i n gt om i r t a z a p i n ea m o n gp a t i e n t sw h oh a v en o t
remitted on the first line treatment by week 3.The pri-
mary outcome is the change in the PHQ-9 scores at
week 4 through 9. Step III represents a continuation
phase to Steps I and II and aims to establish longer-
term effectiveness and acceptability of the above-exam-
ined treatment strategies up to week 25.
Discussion
The trial is first pragmatic mega trial of psychiatry in
Japan. We are now going a pilot phase in the trial. The
pilot phase is supported by the Grant-in-Aid by the
Ministry of Health, Labour and Welfare, Japan.
Trial registration ClinicalTrials.gov identifier:
NCT01109693.
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